Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today

United Therapeutics (NASDAQ:UTHR) has outperformed the market over the past 5 years by 20.86% on an annualized basis producing an average annual return of 33.79%. Currently, United Therapeutics has

Benzinga17:30 ET

Cerevel Therapeutics Gains as Investors Appear More Confident on FTC Approval for AbbVie

Seeking Alpha16:03 ET

$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 17.42% on an annualized basis producing an average annual return of 29.68%. Currently, Regeneron

Benzinga15:00 ET

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

HC Wainwright analyst initiated coverage on AnaptysBio Inc (NASDAQ:ANAB), a clinical-stage biotechnology company focused on delivering immunology therapeutics.AnaptysBio has a pipeline of checkpoint

Benzinga14:53 ET

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst

Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results Monday from the completed multiple ascending dose (MAD) portion of the Phase 1/2 open-label study of ION582 in people with Angelman syndrome (

Benzinga13:04 ET

A Glimpse Into The Expert Outlook On Biomarin Pharmaceutical Through 10 Analysts

Ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) were provided by 10 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The following table encapsulates their

Benzinga13:00 ET